Close Menu

NEW YORK (GenomeWeb News) – Clinical Data today said that it has completed a $50 million convertible debt financing with New River Management V and another affiliate of Randal J. Kirk, chairman of Clinical Data's board of directors.

The Newton, Mass.-based firm, which makes pharmacogenetic tests and is developing therapeutics, said that the funds would be used primarily to support late-stage therapeutics development. It has two compounds in Phase III studies: vilazodone for treating depression, and Stedivaze, a cardiac stress agent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.